Cargando…

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer

Background: Programmed cell death protein 1(PD-1) blockade has become a standard second-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without a driver gene mutation. Previous clinical studies showed that the objective response rate (ORR) of PD-1 blockade as seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lingdi, Ma, Baozhen, Yang, Yonghao, Li, Tiepeng, Han, Lu, Gao, Quanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186846/ https://www.ncbi.nlm.nih.gov/pubmed/32373522 http://dx.doi.org/10.3389/fonc.2020.00507

Ejemplares similares

Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
por: Zhao, Lingdi, et al.
Publicado: (2019)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies
por: Huang, Hao, et al.
Publicado: (2022)

Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients
por: Liu, Xiao, et al.
Publicado: (2021)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
por: Xing, Wenqun, et al.
Publicado: (2021)

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study
por: Zhao, Lingdi, et al.
Publicado: (2022)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
por: Zhao, Lingdi, et al.
Publicado: (2015)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
por: Shen, Qian, et al.
Publicado: (2021)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
por: Xiang, Xiaoyong, et al.
Publicado: (2023)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti–PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients
por: Ren, Qianqian, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors
por: Wu, Zhaozhen, et al.
Publicado: (2022)

One Cycle of Concurrent Chemotherapy vs. Two Cycles of Concurrent Chemotherapy With Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer
por: Yu, Hao, et al.
Publicado: (2022)

Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review
por: Jia, Guohua, et al.
Publicado: (2022)

Nestin Expression Affects Resistance to Chemotherapy and Clinical Outcome in Small Cell Lung Cancer
por: Sone, Kazuki, et al.
Publicado: (2020)

Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs
por: Wei, Kunchen, et al.
Publicado: (2023)

Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy
por: Yi, Xiaoping, et al.
Publicado: (2022)

Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer
por: Zhou, Li, et al.
Publicado: (2021)

Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review
por: Zhang, Yong, et al.
Publicado: (2017)

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients
por: Fang, Chao, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
por: Wang, Peiliang, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Chen, Shubin, et al.
Publicado: (2021)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3efb94a71r37lv7nn5tl2qc2qt